10000 IU
Trade Name
Spectrila
Powder for concentrate for solution for infusion
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adult